Date: 2014-11-06
Type of information: Presentation of results at a congress
phase: 3
Announcement: presentation of results at the Annual Meeting of the American Association for the Study of Liver Diseases, also known as The Liver Meeting®, taking place November 7-11, 2014, in Boston
Company: Eisai (Japan) Arena Pharmaceuticals (USA - CA)
Product: lorcaserin HCl
Action mechanism:
Disease: overweight or obese patients with and without type 2 diabetes mellitus
Therapeutic area: Metabolic diseases
Country:
Trial details:
Latest
news: * On November 6, 2014, Eisai and Arena Pharmaceuticals announced that data from the Phase 3 clinical trial program for lorcaserin HCl will be presented at the Annual Meeting of the American Association for the Study of Liver Diseases, also known as The Liver Meeting®, taking place November 7-11, 2014, in Boston, Massachusetts. The following poster will be presented: Lorcaserin Improves the NASH Clinical Score in the Majority of High-Risk Patients: A Retrospective Analysis of Three Phase III Studies. This post-hoc analysis evaluated the ability of lorcaserin to improve NASH (nonalcoholic steatohepatitis) clinical score and liver function test parameters (ALT, AST) in overweight or obese patients with and without type 2 diabetes mellitus.
